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Human cartilage glycoprotein-39 (HC gp-39) is highly expressed 
on Foxp3+ Treg cells, and inhibits the proliferation  
and cytokine production of antigen-specific Th1 and Th17 cells 
in GPI-induced arthritis model. 
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 1 
Abstract 
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized 
by inflammation of the multiple joints. In patients with RA, several reports indicate 
the presence of clonally expanded blood and synovial CD4+ T cells. Recently, biologic 
agents targeting T cell co-stimulation have clear therapeutic benefits on patients with 5 
RA, suggesting CD4+ T cells play a crucial role in the pathogenesis. However, their 
precise function to RA is poorly defined. In this study, we focused on specific 
molecule in antigen-specific CD4+ T cells and explored the mechanisms in 
GPI-induced arthritis (GIA) model. 
We evaluated highly expressed molecules of CD4+ T cells from splenocytes 10 
of GIA mice by GeneChip analysis, and we focused on human cartilage 
glycoprotein-39 (HC gp-39). HC gp-39 is a well-known autoantigen in rheumatoid 
arthritis (RA). However, the exact localization, fluctuation, and function of HC gp-39 
in RA are unknown. Therefore, using a GIA model, we investigated these aspects of 
HC gp-39 in arthritis.  15 
 2 
The production of HC gp-39 was highly detected on the early phase of GIA 
(day 7) and the HC gp-39 mRNA was significantly increased on splenic CD4+ T cells 
on day 7 but not on CD11b+ cells. Moreover, to identify the characterization of HC 
gp-39+CD4+ T cells, we assessed the analysis of Th subsets. As a result, HC gp-39 was 
dominantly expressed in CD4+CD25+Foxp3+ Treg cells, but not in Th1 and Th17 cells. 20 
Furthermore, to investigate the effect of HC gp-39 to CD4+ T cells, we assessed T cell 
proliferation assay and cytokine production from CD4+ T cells using recombinant HC 
gp-39. We found that GPI-specific T cell proliferation, and IFNγ or IL-17 production 
were clearly suppressed by addition of recombinant HC gp-39.  Antigen-specific 
expression of HC gp-39 in splenic CD4+CD25+ Foxp3+ Treg cells occurs in the 25 
induction phase of GIA, and addition of recombinant HC gp-39 suppresses 
antigen-specific T cell proliferation and cytokine production, suggesting that HC 
gp-39 in CD4+ T cells might play a regulatory role in arthritis.  
  
 3 
Chapter. 1 Introduction 30 
Rheumatoid arthritis (RA) is characterized by chronic inflammation of 
multiple joints and variable disease outcomes. Biologic agents targeting 
proinflammatory cytokines, such as TNFα and IL-6, as well as T cell costimulation 
have clear therapeutic benefits on patients with RA 1), although its etiology is poorly 
understood.  35 
Glucose-6-phosphate isomerase (GPI) is an autoantigen that was identified 
in KxB/N mice 2) ; it also induces arthritis in DBA/1 mice after a single immunization 
(GPI-induced arthritis: GIA) 3, 4). In this model, the development of arthritis depends 
on T cells, B cells, and inflammatory cytokines, and the therapeutic effectiveness of 
biologics closely resembles that for human RA 4, 5). Notably, the GPI-reactive T cells 40 
of this model are skewed to Th1 and Th17 cells, and T cell targeting therapies such as 
anti-CD4, CTLA-4 Ig, anti-ICOS, and anti-IL-17antibodies are clearly effective in 
treating GIA 3-6), whereas IFNγ receptor deficient mice were less susceptible to GIA 7), 
highlighting the critical role of antigen-specific T cells.  Thus, unique expression of 
 4 
an unknown molecule in autoreactive T cells might mirror a corresponding unique 45 
expression in RA. 
Human cartilage glycoprotein-39 (HC gp-39; also termed BRP-39 or 
chitinase 3-like 1) is a well- known biomarker of several inflammatory autoimmune 
diseases:, elevated serum levels of HC gp-39 are seen in patients with RA, systemic 
lupus erythematosus (SLE), multiple sclerosis (MS) and  asthma 8-10).  Indeed, 50 
elevated serum levels of HC gp-39 in RA are positively correlated with inflammatory 
cytokines and arthritis biomarkers such as IL-6 and CRP 11). Also, HC gp-39 has been 
the focus of studies investigating it as a candidate autoantigen in RA 12-14), owing to its 
different expression in cartilage and synovial tissues, and to a possible link with the 
HLA-DR4 shared epitope 12, 13). HC gp-39 protein is expressed in neutrophils, 55 
macrophages, chondrocytes, and synoviocytes 15). Lee et al reported that in a HC 
gp-39 deficient murine model of asthma, disease state was improved as a result of 
diminished antigen-induced Th2 cell responses, suggesting an essential role in antigen 
sensitization by Th2 cells 16, 17). However, the expression of HC gp-39 and its function 
in T cells in arthritis remain unclear.  60 
 5 
In this report, we show that HC gp-39 is upregulated in antigen-specific 
CD4+CD25+ Foxp3+ Treg cells in the early phase of arthritis, and that addition of HC 
gp-39 suppresses the proliferation and cytokine production of antigen-specific CD4+ T 
cells, suggesting a crucial role for HC gp-39 in the regulation of T cells in arthritis. 
  65 
 6 
Chapter 2. Materials and Methods 
2-1. Mice 
DBA/1 male mice and C57BL/6 male mice were obtained from Charles 
River Laboratories (Yokohama, Japan). All mice used in these studies were aged 
between 6 and 8 weeks and maintained under specific pathogen-free conditions. All 70 
experiments were approved by and conducted in accordance with the guidelines of the 
Ethics Review Committee for Animal Experimentation of the University of Tsukuba. 
 
2-2. The mouse model of arthritis 
Recombinant human GPI was prepared as described previously (4). The 75 
mice were immunized by intradermal injection of 300 µg recombinant human 
GPI-GST in emulsified Freund’s complete adjuvant (CFA) (Difco, Detroit, MI, USA). 
Control mice were immunized with 100 µg GST in CFA. The arthritic mice were 
assessed visually, and changes in each paw were scored on a scale 0 to 3-; a score of 0 
indicated no evidence of inflammation-; of 1, subtle inflammation or localized 80 
 7 
edema-; of 2, easily identified swelling but localized to the dorsal or ventral surface of 
the paws-; and of 3, swelling of all aspects of the paws. The maximum possible score 
per mouse was 12.  
 
2-3. GeneChip Analysis 85 
Splenic CD4+ T cells were collected from three DBA/1 mice (arthritis 
susceptible) and three C57BL/6 mice (arthritis resistant, as a control) after 
immunization of GPI on day7. Total RNA was extracted from these CD4+ T cells 
using ISOGEN (Nippon Gene Co., Ltd., Toyama, Japan), and then 15 μg of RNA was 
used for cDNA synthesis by reverse transcription followed by the synthesis of 90 
biotinylated cRNA through in vitro transcription. After cRNA fragmentation, 
hybridization with mouse 430A2.0 GeneChip (Affymetrix, Santa Clara, CA, USA) 
with probes for 43,000 mouse gene ESTs (expressed sequence tags) was performed in 
accordance with the protocol provided by the manufacturer. Analysis was performed 
by gene expression software (GEO- GSE66912). 95 
 8 
 
2-4. ELISA 
Sera were obtained from DBA/1 mice after GPI immunization (days 0, 7, 14, 
28), or culture supernatants in which the splenocytes were stimulated with 
anti-CD3/28 and GPI for 48 and 24 hours, respectively, were collected. The HC gp-39 100 
protein in the sera and culture supernatants was analyzed using the HC gp-39 ELISA 
kit (R&D Systems, Minneapolis, MN). 
 
2-5. Quantitative PCR analysis 
After GPI immunization (days 0, 7, 14, 28), the spleens, lymph nodes and 105 
joints were isolated, cut into small pieces, and passed through cell strainers (BD 
Biosciences, Erembodegem, Belgium) to obtain single-cell suspensions. CD4+, 
CD11b+ and CD19 cells were isolated from the splenocytes by means of 
magnetic-activated cell sorting (MACS) (miltenyi Biotech, Bergisch Gladback, 
Germany). The remaining cells were washed with phosphate-buffered saline (PBS). 110 
Total RNA was extracted with Isogen reagents (Nippon Gene Inc, Tokyo, Japan) 
 9 
according to the manufacturer’s. cDNA was obtained by reverse transcription with a 
commercially available kit (PrimeScript RT Master Mix; Takara). For quantitative 
PCR, we used a TaqMan Assay-on-Demand gene expression product (Applied 
Biosystems, Foster City, CA, USA). The expression levels of HC gp-39 and GAPDH 115 
(assay ID Mm00901477_m1 and Mm99999915_g1, respectively; Applied 
Biosystems) were normalized relative to the expression of GAPDH. Analysis was 
performed with an ABI Prism 7500 apparatus (Applied Biosystems) under the 
following conditions: inactivation of possible contaminating amplicons with 
AmpErase UNG (Applied Biosystems) for 2 minutes at 50℃ initial denaturation for 120 
10 minutes at 95℃, followed by 45 thermal cycles of 15 seconds at 95℃ and of 60 
seconds at 60℃.  
 
2-6. Western blot analysis 
Splenocytes were obtained from DBA/1 mice after GPI immunization (days 125 
0, 7, 14, 28). Cells were lyzed overnight in ice-cold lysis buffer (50mM Tris-HCl 
pH7.4, 5mM MgCl2, 2mM PMSF, 0.5% NP-40). The lysates were centrifuged at 
 10 
15,000 rpm for 30 minutes at 4℃,and the supernatants collected. The lysates were 
subjected to electrophoresis on SDS-polyacrylamide gel (7.5%-15%). After transfer, 
the membranes were blocked for 60 minutes with Block Ace solution and then 130 
incubated with rat anti-HC gp-39 or rabbit anti-α actin diluted in Can Get Signal 
solution 1 (Toyobo Corporation, Osaka, Japan). After 60 minutes, the membranes 
were washed with PBS in 0.05% Tween-20 and incubated with mouse anti-rat HRP 
and goat anti-rabbit HRP diluted in Can Get Signal solution 2. The proteins were 
visualized by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech NJ 135 
USA) according to the manufacturer’s instructions. Analysis was performed with an 
ImageQuant LAS 4000 apparatus (Fujifilm). 
 
2-7. Fluorescent activated cell-sorting (FACS) analysis 
Splenocytes obtained from day 7 DBA/1 mice after GPI immunization were 140 
restimulated with GPI or control for 24 hours in vitro. After that, these cells were 
stained with specific antibodies to CD4 (biolegend), HC gp-39 (Bioss), IFNγ 
(biolegend), IL-17 (biolegend) and Foxp3 (ebioscience). Intracellular staining was 
 11 
used BD Cytofix/Cytoperm Plus Fixtation/Permeabilization kit (BD biosciences) and 
Treg staining kit. Flow cytometry was conducted using a FACSCalibur flow 145 
cytometer (BD Biosciences), and data were analyzed with FlowJo software (Tree Star, 
Ashland, OR, USA). 
 
2-8. Cell proliferation assay 
Naïve CD4+ T cells (2 x 106 cells) isolated from splenocytes or GPI-reactive 150 
CD4+ T cells from lymph node on day 7 after GPI immunization were stained with 
1.25 μM carboxyfluorescein diacetate succinimidyl ester (CFSE) for 7 minutes. The 
stained cells were stimulated with 1 μg/ml anti-CD3/28 antibodies or 5.0μg/ml GPI in 
the presence of antigen presenting cells, respectively. Then, 10 μg/ml recombinant 
mouse HC gp-39 (R&D) (rHC gp-39) or as a control ovalbumin (OVA) was added in 155 
the presence of 1 x 106 cells/ml in 96-well round-bottom plates for 72 hours. 
 
2-9. Co-culture 
 12 
The mice were killed on day 7 after GPI immunization, and CD4+ T cells and 
CD11c+ cells were obtained from the lymph nodes and spleens, respectively, by 160 
means of MACS. The CD4+ T cells and CD11c+ cells were then co-cultured with 5 
μg/ml GPI in the absence or presence of rHC gp-39, and as a control protein, 
ovalubumin (OVA) at a ratio of 5:1 for 72 hours. The supernatants were collected, and 
IFNγ and IL-17, measured using ELISA (R&D). 
 165 
2-10. Histologic examinations 
The hind paws and ankles were obtained from GIA mice (day 14). These 
samples were fixed in 10% formalin and stained with goat anti-HC gp-39 antibody 
(Santa Cruz Biothecnology, Santa Cruz CA) and hematoxylin. 
 170 
2-11. Statistical analysis 
All data were expressed as means ± SEMs. Differences between groups were 
examined for statistical significance using the t test. Probability values less than 0.05 
were considered to indicate statistical significance.
 13 
Chapter 3. Results 175 
3-1. HC gp-39 was identified as a highly expression molecules in arthritic CD4+T 
cells by GeneChip analysis.  
CD4+ T cells are indispensable for both the induction and the effector phase 
of GIA 4). To identify the highly expressed molecules of CD4+ T cells in GIA, we 
assessed the GeneChip analysis. The expression of mRNA profile was examined in 180 
splenic CD4+ T cells from DBA/1 mice (arthritis susceptible) and C57BL/6 mice 
(arthritis resistant) after immunization of GPI on day 7 (induction phase). Twenty 
genes were upregulated on the CD4+ T cells from DBA/1 mice on GeneChip (GEO- 
GSE66912, Table.1). Among them, we focused on the molecules contribute to 
immune system such as HC gp-39. 185 
 
3-2. HC gp-39 was highly detected in serum and CD4+ T cell from GIA mice  
To determine the correlation between HC gp-39 and GIA, the time-course 
production and expression of the protein was analyzed.  For the control, mice were 
 14 
immunized with a tagged protein (GST). Serum HC gp-39 levels were clearly elevated 190 
on day 7 (onset of arthritis), and then gradually increased, peaking on day 14 (peak of 
arthritis), where after they subsided to the basal level by day 28 (attenuate of arthritis) 
(Fig. 1a). We also assessed the fluctuated expression of HC gp-39 at the splenocytes 
by quantitative PCR and Western blotting. The expression of HC gp-39 was highly 
detected in the splenocytes of GIA mice on day 7 (Fig. 1b). Next, the splenocytes 195 
from GIA mice were separated into CD4+ T cells, CD11b+ cells and CD19+ cells. Then, 
fluctuation of HC gp-39 mRNA was analyzed in the individual cell populations. Of 
these, CD4+ T cells had clear antigen-specific upregulation of HC gp-39 mRNA on 
days 7 and 14, which was confirmed by quantitative PCR. On the other hand, the 
CD11b+ cells showed higher HC gp-39 expression on days 7 and 14, but a comparable 200 
amount of expression was noted in the control- GST- immunized mice. CD19+ cells 
demonstrated only weak upregulation of HC gp-39 on day 14 (Fig. 1c). These findings 
suggest that arthritis-specific overproduction of HC gp-39 is dominated by CD4+ T 
cells.  
 205 
 15 
3-3. HC gp-39 was highly expressed in CD4+CD25+ T cells, but not Th1 and Th17 
cells in GIA 
To confirm GPI-specific overproduction of HC gp-39 in splenocytes, we 
cultured splenocytes from GPI immunized mice with GPI or control stimulation and 
the production of HC gp-39 was analyzed. The production of HC gp-39 in the 210 
supernatants was induced by GPI stimulation, but not by control stimulation (Fig. 2a).  
This findings was also confirmed by FACS staining of HC gp-39 expression in CD4+ 
T cells (Fig. 2b). As the GIA model is clearly skewed to Th1 and Th17 cells in 
arthritic conditions 3-5), to analyze HC gp-39 overexpression in Th cell subsets such as 
Th1 and Th17 cells, we performed intracellular FACS staining. We did not detect 215 
clear overexpression in either the Th1 or the Th17 cells as compared with the control 
stimulation cells (Fig. 2c). To further reveal HC gp-39 positive T cell populations, we 
also screened CD25+ cells, because it was reported that depletion of CD25+ cells 
results in non-limiting arthritis in a model of GIA 18). HC gp-39 positive cell 
population was detected in CD4+CD25+ T cells when compared with the control 220 
stimulation cells.  
 16 
3-4. HC gp-39 was expressed in CD4+CD25+Foxp3+ Treg cells and produced as a 
soluble protein 
Next, to confirm the HC gp-39 protein association between serum and 
CD4+CD25+ T cells, we examined the soluble HC gp-39 proteins from GPI-reactive 225 
CD4+CD25+ T cells using ELISA system. We purified CD4+CD25+ T cells from GIA 
from lymph node on day 7, then co-cultured with antigen-presenting cells (APC) with 
GPI for 96 hours. The production of HC gp-39 from GPI-reactive CD4+CD25+ T cells 
was clearly overproduced. Moreover, to abolish the possibility that the HC gp-39 was 
produced by APC, we also cultured APC only, but the production of HC gp-39 from 230 
APC was not detected (Fig. 2e). We also checked the expression of HC gp-39 in Treg 
cells (CD4+CD25+Foxp3+ T cells) and effector T cells (CD4+CD25- T cells). As a 
result, HC gp-39 was highly detected on Treg cells compared with effector T cells 
(Fig. 2f). Taken together, these findings suggest that HC gp-39 is dominantly 
expressed in GPI-specific CD4+CD25+ Foxp3+Treg cells, but not in Th1 and Th17 235 
cells in GIA.  
 
 17 
3-5. Antigen-specific T cell proliferation and cytokine production are suppressed 
by addition of recombinant HC gp-39 
We also speculated that overproduction of HC gp-39 can enhance or 240 
suppress T cell proliferation. The addition of recombinant HC gp-39 did not suppress 
the proliferation of CD4+ T cells induced by CD3 and CD28 stimulation, which was 
confirmed by CFSE labeling (Fig. 3a). Moreover, if we used antigen-specific culture 
conditions, T cell proliferation was suppressed by addition of HC gp-39 (Fig. 3b).  
Finally, antigen-specific overproduction of both IFNγ and IL-17 was clearly 245 
suppressed by HC gp-39 (Fig. 3c). These findings suggest that HC gp-39 itself may 
suppress antigen-specific T cells, especially Th1 and Th17 cells, in the early phase of 
arthritis.  
 
3-6. Localization of HC gp-39 protein in cells infiltrated into the arthritic 250 
synovium  
HC gp-39 is basically a cartilage-dominant protein. To check the association 
between joint specific fluctuation of HC gp-39 and arthritis, we checked the time 
 18 
course of HC gp-39 expression in joints. HC gp-39 was clearly overexpressed on day 
14 and was accompanied by joint swelling (Fig. 4a). Next, immunohistochemical 255 
analysis was conducted to determine the distribution of HC gp-39 in the arthritic joints. 
HC gp-39 was clearly detected in the cells infiltrating the arthritic synovium, which 
included neutrophils and monocytes (Fig. 4b). For detailed investigation of the 
expression of HC gp-39 in these cells, the arthritic joints were harvested and the 
acquired cells were analyzed by FACS. HC gp-39 was expressed mainly in the CD4 260 
negative cells, suggesting different localization and upregulation of this molecule in 
splenocytes within joints (Fig. 4c).  
  
 19 
Chapter. 4 Discussion 
In this study, we clearly detected unexpected expression of HC gp-39 in 265 
antigen-specific T cells of a GIA model, particularly in CD4+CD25+Foxp3+ Treg cells.  
HC gp-39 is also known as YKL-40, BRP-39, and chitinase 3-like 1 19). It is 
a secretory protein that is upregulated in a wide variety of inflammatory disorders 7-11, 
15, 19).  It is also expressed by a variety of cells, including macrophages, neutrophils, 
synoviocytes, and chondrocytes 19, 20).  Its functional roles such as augmention of Th2 270 
immunity, regulation of apoptosis, and stimulation of alternative macrophage 
activation have recently been elucidated 16, 17). 
In RA, increased levels of HC gp-39 have been demonstrated in plasma 8) 
and synovial fluid, and it has also been plotted as a multi- biomarker 21). As a major 
constituent of human cartilage, HC gp-39 is considered a candidate autoantigen in RA 275 
12-14). Intranasal administration of HC gp-39 in collagen type II (CII)-induced arthritis 
after immunization (days 20, 25, 30) clearly suppressed arthritis and was associated 
with decreased levels of anti-CII antibody, whereas administration of CII over the 
 20 
same time course was ineffective. In addition, HC gp-39 administration before 
immunization with CII was found to be ineffective 22). Joosten et al. speculated that 280 
HC gp-39 might trigger a regulatory mechanism by cross- tolerance. However, we 
expected that one of the explanations for this suppressive mechanism after CII 
immunization is the blocking of antigen-specific T cell proliferation in the arthritic 
condition, which was confirmed by the findings depicted in Figure 3B. 
In terms of the T cell subtype of HC gp-39, Lee et al. confirmed that BRP-39 285 
(HC gp-39) plays a critical role in the pathogenesis of Th2-driven asthma 16, 20), 
however, we could not find any antigen Th2- type cells in our arthritis model.  We 
also checked antigen-specific Th1 and Th17 cells, but those cells were mostly HC 
gp-39 negative (Fig. 4c).  
Frey et al. confirmed that depletion of CD25+ cells (before immunization) in 290 
GIA results in sustained severe arthritis 18). In this study, we demonstrated that HC 
gp-39 is expressed on CD4+CD25+Foxp3+ Treg cells. Moreover, it is possible that the 
HC gp-39 from CD4+CD25+ T cells and in serum is the same molecule (Fig.2e). Thus, 
HC gp-39 produced by Treg cells suppress the production of IFNγ and IL-17 via 
 21 
inhibition of proliferation on antigen-specific Th1 and Th17, which may in turn 295 
control self-limiting GIA in vivo. 
Among the peripheral blood mononuclear cells of RA patients, the cellular 
source of HC gp-39 was identified as CD16+ monocytes 23). In our experiments, the 
CD11b+ cells were indeed the major source of HC gp-39 in splenocytes, although the 
control immunization mice also expressed comparable amounts of HC gp-39 (Fig. 1c). 300 
We demonstrated that antigen-specific T cells themselves express HC gp-39 in the 
early phase of arthritis. Intranasal administration of HC gp-39 was also conducted in 
human RA, but in phase II, the treatment lacked efficacy when compared with the 
placebo 24). We need to further characterize whether human antigen-specific T cells 
express HC gp-39 in the induction phase of RA.  305 
 
  
 22 
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Chapter. 7 Figure lengends 415 
Figure 1.  
Systemic upregulation of HC gp-39 is dominant in CD4+ T cells in the early phase 
of GIA 
(A) Serum HC gp-39 from DBA/1 mice immunized with GPI (■; n = 5) or control 
(GST-protein) (□; n = 5) was measured by ELISA. (B) The expression of HC gp-39 420 
mRNA (upper panel) in splenocytes was analyzed by quantitative PCR after GPI 
immuniazation (■; n = 5) or control immunization (□; n = 5). The expression of HC 
gp-39 (lower panel) in splenocytes was detected by Western blot analysis.  (C) The 
expression of HC gp-39 mRNA in CD4+ T cells, CD11b+ cells and CD19+ cells was 
analyzed by quantitative PCR after GPI immunization(■; n = 5) or control 425 
immunaization (□; n = 5). **p <0.01, t- test.  
 
Figure 2. 
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HC gp-39 in CD4+ T cells was increased by GPI stimulation, particularly in the 
CD25+ population  430 
(A) Splenocytes from GPI immunized DBA/1 mice on day 7 were restimulated with 
GPI or control for 24 hours in vitro, and production of HC gp-39 in the culture 
supernatants was measured by ELISA. (B) Splenocytes obtained on day 7 were 
restimulated with GPI or control for 24 hours in vitro, and FACS of HC gp-39 in 
CD4+ T cells, (C) IFNγ or IL-17 cells, and (D) CD25+ cells was performed, (to gate 435 
the CD4+ T cells). (E) CD4+CD25+ T cells were sorted from from lymph node on day7, 
and co-cultured APC with GPI for 96 hours. Then, the HC gp-39 from CD4+CD25+T 
cells in the culture supernatants was measured by ELISA. (F) In the same way as Fig 
2C, the expression of HC gp-39 on Treg cells was analyzed by FACS. *p < 0.05, **p 
< 0.01, by t-test.  440 
 
Figure 3. 
Recombinant HC gp-39 suppressed the proliferation and cytokine production of 
GPI-specific CD4+ T cells. (A) CD4+ T cells from naïve DBA/1 mice were stained 
 32 
with carboxyfluorescein diacetate succinimidyl ester (CFSE-DA) and stimulated with 445 
anti-CD3 (1 μg/ml) and anti-CD28 (1 μg/ml) antibodies in the absence or presence of 
recombinant HC gp-39 (rHC gp-39) for 72 hours in vitro. (B, C) Lymph nodes were 
collected from GPI- immunized DBA/1 mice on day 7, and cells were stained with 
CFSE-DA cultured with stimulation media, GPI, or control in the absence or presence 
of rHC gp-39 or OVA for 72 hours in vitro. Then, the proliferation of GPI-specific 450 
CD4+T cells was analyzed by FACS, and the production of IFNγ and IL-17 in the 
supernatants, analyzed by ELISA.  *p < 0.05, t-test.  
 
Figure 4. 
Fluctuation and localization of HC gp-39 in arthritic joints 455 
(A) Expression of HC gp-39 mRNA in joints were analyzed by quantitative PCR after 
GPI immunization (■; n = 5) or control immunization (□; n = 5). (B) Localization of 
HC gp-39 in the joints on day 14 was detected by immunofluorescence. (C) Cells 
isolated from the joints of GIA mice on day 14 were analyzed by FACS. *p < 0.05, 
t-test.  460 
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Table 
 Table 1. 
The identification of the strong expression molecule in CD4+T cells with 
GeneChip analysis 
 465 
Symbol 
    NCBI 
accession no. 
                  Description 
 Fold 
change 
Stab2 NM_138673.1 stabilin 2 4 
Scg5 AK019337.1 secretogranin V 4 
Fpr2 NM_008039.1 formyl peptide receptor 2 3.8 
Ighg1 AF466769.1 
immunoglobulin heavy constant gamma 1 (G1m 
marker) 
3.6 
Stfa3 NM_025288.1 stefin A3 3.3 
Hp NM_017370.1 haptoglobin 3.2 
Spon1 BC020531.1 spondin 1a 3.2 
Cap1 BC005446.1 CAP, adenylate cyclase-associated protein 1 3.1 
Chi3l1 BC005611.1 chitinase 3-like 1 (cartilageglycoprotein-39) 3 
Ccr1 BC011092.1 chemokine (C-C motif) receptor 1 2.9 
Pla2g7 AK005158.1 
phospholipase A2, group VII (platelet-activating 
factor acetylhydrolase, plasma) 
2.9 
Serpinb1a AF426024.1 
serine (or cysteine) peptidase inhibitor, clade B, 
member 1a 
2.7 
Cd177 BC027283.1 CD177 antigen 2.7 
Slfn4 AF099975.1 schlafen 4 2.7 
Anxa1 NM_010730.1 annexin A1 2.7 
Mlycd NM_019966.1 malonyl-CoA decarboxylase 2.7 
Hebp1 AF117613.1 heme binding protein 1 2.6 
Olfm1 D78264.1 olfactomedin 1 2.6 
Supt16 AW536705 suppressor of Ty 16 2.6 
Ifitm1 BC027285.1 interferon induced transmembrane protein 1 2.5 
 34 
The mRNA expression profile of splenic CD4+ T cells was examined by 
microarray in DBA/1 mice (arthritis susceptible) and B6 mice (arthritis resistant) 
after immunization of GPI and then, the highly expression molecules which is 
GIA specific was selected (20 molecules). 
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